

Name of Disorder:

Myasthenia gravis

Essay Title:

Myasthenia gravis

Title/First Name/Surname/Qualifications:

Dr. Marco Morsch | PhD

Institution:

Discipline of Physiology
School of Medical Sciences and Bosch Institute

The University of Sydney
Anderson Stuart Bldg (F13), Room E301
University of Sydney | NSW | 2006
Australia

Date:

17/06/2013

Content:

Myasthenia gravis (MG) is the most common disorder of the neuromuscular junction (NMJ), the connection between motor nerve and voluntary muscle. Patients suffer from fatigue and muscle weakness due to impaired communication between the nerve and the muscle fibre. In MG the immune system produces antibodies that attack the NMJ, disrupting its function. In approximately 80% of MG patients, the antibodies bind to and interfere with the acetylcholine receptor (AChR): the receptor through which the muscle receives chemical signals from the nerve [1, 2]. As many as half of the remaining MG patients instead have autoantibodies against an important regulatory protein called Muscle Specific Kinase (MuSK) [3-5]. Another small number of patients instead have antibodies against low-density lipoprotein receptor-related protein 4 (LRP4): a protein that works together with MuSK to regulate the NMJ [6, 7]. Progression of MG may be similar in patients with these three forms of autoimmune MG cases, but there are typically differences in age at onset, involvement of thymus and in the maximum severity. The different autoantibodies seem to differentially affect muscles in different parts of the body.

In a healthy muscle, the motor nerve terminal releases the neurotransmitter acetylcholine which acts via the AChRs on the muscle surface to initiate the muscle action potential and contraction. Effective neurotransmission depends upon the tight packing of muscle AChRs into clusters immediately beneath the nerve terminal (the sites of acetylcholine release). In MG the numbers of these postsynaptic AChRs are usually reduced. Patients then can suffer from fluctuating muscle weakness and fatigue as the postsynaptic response to acetylcholine becomes marginal.

Autoantibodies against AChR (anti-AChR) can cause damage by recruiting the complement membrane attack complex of the innate immune system [4, 8]. By binding directly to the AChRs, anti-AChR antibodies can also cause the more rapid catabolism of the AChRs. Both these pathogenic mechanisms tend to reduce the

ability of the muscle AChRs to respond to acetylcholine released from the nerve. Autoantibodies against MuSK (anti-MuSK) also seem to disrupt NMJ signalling by reducing the number of AChRs at the NMJ, but different pathogenic mechanisms are involved. Recent studies in experimental animals suggest that anti-MuSK antibodies act to remove MuSK from the NMJ. This leads to a reduction in the number and density of AChRs without involving complement attack upon the NMJ [8-10]. In both anti-AChR and anti-MuSK MG the deterioration in AChR numbers progresses so that the ability of the nerve to trigger contraction becomes marginal and often fails upon repeated activation, causing fatigue. The mechanism by which LRP4 antibodies cause impairment of the NMJ has so far not been described but is presumably similar to the effects of anti-MuSK.

MuSK and LRP4 are both concentrated with AChRs and help to ensure they remain densely packed at the NMJ. The MuSK-LRP4 complex plays a central coordinating role in the formation of the NMJ during development [11]. Recent work suggests that MuSK remains important in organising the NMJ throughout life. Thus if the amount of MuSK at the endplate is reduced (as occurs when anti-MuSK patient antibodies are injected into mice), loss of this organiser leads to wastage of the AChRs. Our recent findings suggest that this leads directly to failure of acetylcholine signalling and weakness [9]. Findings over the last years have provided further knowledge about the MuSK-LRP4 protein complex and its important role in stabilising these AChRs at the healthy NMJ [12, 13]. This understanding of how the MuSK complex supports the NMJ may allow further insight into the processes of AChR loss in disorders like MG, and may potentially reveal a way in which we can help prevent muscle weakness by preventing the loss of AChRs.

A treatment plan for MG may include drugs to enhance the function of the damaged NMJ as well as treatments aimed at reducing the harmful autoimmune antibodies in the blood. Symptomatic drugs, such as inhibitors like acetylcholinesterase (AChEIs), enhance the actions of acetylcholine at the NMJ and thereby increase the activation of the diminished number of AChRs that remain at the myasthenic NMJ. AChEIs are generally the first-line treatment for most patients [14-16]. However, such AChEIs often become less effective when they are repeatedly used over weeks and months [14]. Clinical observations suggest that AChEIs may not benefit the anti-MuSK form of MG while recent studies in mice raise the possibility that drugs like pyridostigmine might even be harmful in the anti-MuSK form of MG [17]. In AChR-positive MG patients, thymectomy (removal of the thymus) may cause remission by reducing levels of anti-AChR antibodies in the blood. Individually tailored immunosuppressive therapy using a range of different drugs is so far still the most effective therapy and may be supplemented by plasma exchange (replacement of the antibody-containing fluid of the blood) in more severe cases of MG.

References:

1. Engel, A.G., et al., *Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model*. Neurology, 1977. **27**(4): p. 307-15.

2. Toyka, K.V., et al., *Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice*. N Engl J Med, 1977. **296**(3): p. 125-31.
3. Gomez, A.M., et al., *Antibody effector mechanisms in myasthenia gravis-Pathogenesis at the neuromuscular junction*. Autoimmunity, 2010. **43**(5): p. 1-18.
4. Hoch, W., et al., *Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies*. Nat Med, 2001. **7**(3): p. 365-8.
5. Vincent, A., et al., *Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets*. Lancet Neurol, 2003. **2**(2): p. 99-106.
6. Higuchi, O., et al., *Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis*. Ann Neurol, 2011. **69**(2): p. 418-22.
7. Pevzner, A., et al., *Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis*. Journal of Neurology, 2011. **259**(3): p. 427-435.
8. Klooster, R., et al., *Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice*. Brain, 2012: p. DOI: 10.1093/brain/aws025.
9. Morsch, M., et al., *Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors*. Exp Neurol, 2012. **237**(2): p. 286-295.
10. Viegas, S., et al., *Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects*. Experimental Neurology, 2012. **234**(2): p. 506-512.
11. Ghazanfari, N., et al., *Muscle Specific Kinase: Organiser of synaptic membrane domains*. The International Journal of Biochemistry & Cell Biology, 2011. **43**(3): p. 295-298.
12. Wu, H., et al., *Distinct Roles of Muscle and Motoneuron LRP4 in Neuromuscular Junction Formation*. Neuron, 2012. **75**(1): p. 94-107.
13. Yumoto, N., N. Kim, and S.J. Burden, *Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses*. Nature, 2012.
14. Drachman, D.B., *Myasthenia gravis*. N Engl J Med, 1994. **330**(25): p. 1797-810.
15. Richman, D.P. and M.A. Agius, *Treatment of autoimmune myasthenia gravis*. Neurology, 2003. **61**(12): p. 1652-61.
16. Skeie, G.O., et al., *Guidelines for the treatment of autoimmune neuromuscular transmission disorders*. Eur J Neurol, 2006. **13**(7): p. 691-9.
17. Morsch, M., et al., *Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by Muscle Specific Kinase autoantibody*. J Physiol, 2013. **591**(10): p. 2747-2762.